blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3804724

EP3804724 - CDK INHIBITORS FOR TREATING PAH [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  13.10.2023
Database last updated on 09.04.2026
FormerThe patent has been granted
Status updated on  04.11.2022
FormerGrant of patent is intended
Status updated on  10.07.2022
FormerExamination is in progress
Status updated on  19.03.2021
FormerRequest for examination was made
Status updated on  12.03.2021
Most recent event   Tooltip26.12.2025Lapse of the patent in a contracting state
New state(s): TR		published on 28.01.2026  [2026/05]
Applicant(s)For all designated states
Pfizer Inc.
66 Hudson Boulevard East
New York, NY 10001-2192 / US
[2023/14]
Former [2021/15]For all designated states
Pfizer Inc.
235 East 42nd Street
New York, NY 10017 / US
Inventor(s)01 / EVANS, Steve Martin
7 Buehler Road
Bedford MA 01730 / US
 [2022/32]
Former [2021/15]01 / EVANS, Steve Martin
7 Buehler Road
Bedford, MA Massachusetts 01730 / US
Representative(s)Pfizer
European Patent Department
23-25 avenue du Docteur Lannelongue
75668 Paris Cedex 14 / FR
[2021/15]
Application number, filing date20203847.709.10.2017
[2021/15]
Priority number, dateUS201662410566P20.10.2016         Original published format: US 201662410566 P
US201762548629P22.08.2017         Original published format: US 201762548629 P
[2021/15]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3804724
Date:14.04.2021
Language:EN
[2021/15]
Type: B1 Patent specification 
No.:EP3804724
Date:07.12.2022
Language:EN
[2022/49]
Search report(s)(Supplementary) European search report - dispatched on:EP23.02.2021
ClassificationIPC:A61K31/519, A61K31/506, A61P11/00, A61P9/12
[2021/15]
CPC:
A61K31/519 (EP,KR,US); A61K31/496 (KR); A61K31/506 (EP,KR);
A61K45/06 (KR,US); A61P11/00 (EP,KR,US); A61P9/12 (EP,KR,US);
A61K2300/00 (KR); A61K31/5575 (US) (-)
C-Set:
A61K31/519, A61K2300/00 (US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/47]
Former [2021/15]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:CDK-INHIBITOREN ZUR BEHANDLUNG VON PAH[2021/15]
English:CDK INHIBITORS FOR TREATING PAH[2021/15]
French:INHIBITEURS DE CDK POUR LE TRAITEMENT DE LA HTAP[2021/15]
Examination procedure26.10.2020Examination requested  [2021/15]
23.02.2021Date on which the examining division has become responsible
19.03.2021Despatch of a communication from the examining division (Time limit: M04)
27.04.2021Reply to a communication from the examining division
11.07.2022Communication of intention to grant the patent
05.10.2022Fee for grant paid
05.10.2022Fee for publishing/printing paid
05.10.2022Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP17787029.2  / EP3528812
Opposition(s)08.09.2023No opposition filed within time limit [2023/46]
Fees paidRenewal fee
26.02.2021Renewal fee patent year 03
26.02.2021Renewal fee patent year 04
02.11.2021Renewal fee patent year 05
31.10.2022Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY09.10.2017
HU09.10.2017
AL07.12.2022
AT07.12.2022
BG07.12.2022
CZ07.12.2022
DK07.12.2022
EE07.12.2022
FI07.12.2022
HR07.12.2022
LT07.12.2022
LV07.12.2022
MC07.12.2022
NL07.12.2022
PL07.12.2022
RO07.12.2022
RS07.12.2022
SE07.12.2022
SI07.12.2022
SK07.12.2022
SM07.12.2022
TR07.12.2022
NO07.03.2023
GR08.03.2023
IS07.04.2023
PT10.04.2023
[2026/05]
Former [2025/39]CY09.10.2017
HU09.10.2017
AL07.12.2022
AT07.12.2022
BG07.12.2022
CZ07.12.2022
DK07.12.2022
EE07.12.2022
FI07.12.2022
HR07.12.2022
LT07.12.2022
LV07.12.2022
MC07.12.2022
NL07.12.2022
PL07.12.2022
RO07.12.2022
RS07.12.2022
SE07.12.2022
SI07.12.2022
SK07.12.2022
SM07.12.2022
NO07.03.2023
GR08.03.2023
IS07.04.2023
PT10.04.2023
Former [2025/36]CY09.10.2017
AL07.12.2022
AT07.12.2022
BG07.12.2022
CZ07.12.2022
DK07.12.2022
EE07.12.2022
FI07.12.2022
HR07.12.2022
LT07.12.2022
LV07.12.2022
MC07.12.2022
NL07.12.2022
PL07.12.2022
RO07.12.2022
RS07.12.2022
SE07.12.2022
SI07.12.2022
SK07.12.2022
SM07.12.2022
NO07.03.2023
GR08.03.2023
IS07.04.2023
PT10.04.2023
Former [2024/51]AL07.12.2022
AT07.12.2022
BG07.12.2022
CZ07.12.2022
DK07.12.2022
EE07.12.2022
FI07.12.2022
HR07.12.2022
LT07.12.2022
LV07.12.2022
MC07.12.2022
NL07.12.2022
PL07.12.2022
RO07.12.2022
RS07.12.2022
SE07.12.2022
SI07.12.2022
SK07.12.2022
SM07.12.2022
NO07.03.2023
GR08.03.2023
IS07.04.2023
PT10.04.2023
Former [2024/28]AL07.12.2022
AT07.12.2022
CZ07.12.2022
DK07.12.2022
EE07.12.2022
FI07.12.2022
HR07.12.2022
LT07.12.2022
LV07.12.2022
MC07.12.2022
NL07.12.2022
PL07.12.2022
RO07.12.2022
RS07.12.2022
SE07.12.2022
SI07.12.2022
SK07.12.2022
SM07.12.2022
NO07.03.2023
GR08.03.2023
IS07.04.2023
PT10.04.2023
Former [2023/51]AL07.12.2022
AT07.12.2022
CZ07.12.2022
DK07.12.2022
EE07.12.2022
FI07.12.2022
HR07.12.2022
LT07.12.2022
LV07.12.2022
NL07.12.2022
PL07.12.2022
RO07.12.2022
RS07.12.2022
SE07.12.2022
SI07.12.2022
SK07.12.2022
SM07.12.2022
NO07.03.2023
GR08.03.2023
IS07.04.2023
PT10.04.2023
Former [2023/46]AL07.12.2022
AT07.12.2022
CZ07.12.2022
DK07.12.2022
EE07.12.2022
FI07.12.2022
HR07.12.2022
LT07.12.2022
LV07.12.2022
NL07.12.2022
PL07.12.2022
RO07.12.2022
RS07.12.2022
SE07.12.2022
SK07.12.2022
SM07.12.2022
NO07.03.2023
GR08.03.2023
IS07.04.2023
PT10.04.2023
Former [2023/39]AL07.12.2022
AT07.12.2022
CZ07.12.2022
EE07.12.2022
FI07.12.2022
HR07.12.2022
LT07.12.2022
LV07.12.2022
NL07.12.2022
PL07.12.2022
RO07.12.2022
RS07.12.2022
SE07.12.2022
SK07.12.2022
SM07.12.2022
NO07.03.2023
GR08.03.2023
IS07.04.2023
PT10.04.2023
Former [2023/38]AL07.12.2022
AT07.12.2022
CZ07.12.2022
EE07.12.2022
FI07.12.2022
HR07.12.2022
LT07.12.2022
LV07.12.2022
NL07.12.2022
PL07.12.2022
RO07.12.2022
RS07.12.2022
SE07.12.2022
SK07.12.2022
SM07.12.2022
NO07.03.2023
GR08.03.2023
PT10.04.2023
Former [2023/37]AL07.12.2022
AT07.12.2022
CZ07.12.2022
EE07.12.2022
FI07.12.2022
HR07.12.2022
LT07.12.2022
LV07.12.2022
NL07.12.2022
PL07.12.2022
RO07.12.2022
RS07.12.2022
SE07.12.2022
SM07.12.2022
NO07.03.2023
GR08.03.2023
PT10.04.2023
Former [2023/35]AT07.12.2022
CZ07.12.2022
EE07.12.2022
FI07.12.2022
HR07.12.2022
LT07.12.2022
LV07.12.2022
NL07.12.2022
PL07.12.2022
RO07.12.2022
RS07.12.2022
SE07.12.2022
SM07.12.2022
NO07.03.2023
GR08.03.2023
PT10.04.2023
Former [2023/34]EE07.12.2022
FI07.12.2022
HR07.12.2022
LT07.12.2022
LV07.12.2022
NL07.12.2022
PL07.12.2022
RS07.12.2022
SE07.12.2022
SM07.12.2022
NO07.03.2023
GR08.03.2023
PT10.04.2023
Former [2023/33]FI07.12.2022
HR07.12.2022
LT07.12.2022
LV07.12.2022
NL07.12.2022
PL07.12.2022
RS07.12.2022
SE07.12.2022
SM07.12.2022
NO07.03.2023
GR08.03.2023
Former [2023/29]FI07.12.2022
HR07.12.2022
LT07.12.2022
LV07.12.2022
NL07.12.2022
PL07.12.2022
RS07.12.2022
SE07.12.2022
NO07.03.2023
GR08.03.2023
Former [2023/25]FI07.12.2022
HR07.12.2022
LT07.12.2022
LV07.12.2022
PL07.12.2022
RS07.12.2022
SE07.12.2022
NO07.03.2023
GR08.03.2023
Former [2023/23]FI07.12.2022
LT07.12.2022
LV07.12.2022
SE07.12.2022
NO07.03.2023
GR08.03.2023
Former [2023/22]FI07.12.2022
LT07.12.2022
SE07.12.2022
NO07.03.2023
Former [2023/20]LT07.12.2022
NO07.03.2023
Documents cited:Search[A] CN104758292  (TIANJIN MEDICAL UNIV GENERAL HOSPITAL et al.)
 [AD] WO2014128588  (PFIZER et al.)
 [A] WO2015155197  (BAYER PHARMA AG et al.)
 [A] WO2009047359  (INGENIUM PHARMACEUTICALS GMBH et al.)
 [A] EP1097711  (PFIZER LTD et al.)
 [A]   ROSKOSKI ROBERT ED - ACOSTA GABRIELA ET AL: "Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs", PHARMACOLOGICAL RESEARCH, ACADEMIC PRESS, LONDON, GB, vol. 107, 16 March 2016 (2016-03-16), pages 249 - 275, XP029533468, ISSN: 1043-6618, DOI: 10.1016/J.PHRS.2016.03.012

DOI:   http://dx.doi.org/10.1016/j.phrs.2016.03.012
 [A]   SCHERMULY R T ET AL: "Mechanisms of disease: Pulmonary arterial hypertension", NATURE REVIEWS CARDIO, NATURE PUBLISHING GROUP, GB, vol. 8, no. 8, 1 August 2011 (2011-08-01), pages 443 - 455, XP008156988, ISSN: 1759-5002, [retrieved on 20110621], DOI: 10.1038/NRCARDIO.2011.87

DOI:   http://dx.doi.org/10.1038/nrcardio.2011.87
 [A]   N. GALIE ET AL: "The new clinical trials on pharmacological treatment in pulmonary arterial hypertension", EUROPEAN RESPIRATORY JOURNAL, vol. 20, no. 4, 1 October 2002 (2002-10-01), pages 1037 - 1049, XP055165426, ISSN: 0903-1936, DOI: 10.1183/09031936.02.05542002

DOI:   http://dx.doi.org/10.1183/09031936.02.05542002
by applicantWO03062236
 US6936612
 US7208489
 US7456168
 WO2005005426
 US7345171
 US7863278
 WO2008032157
 US7781583
 WO2014128588
 WO2016053040
 WO2007140222
 WO2010075074
 WO2010020675
 WO2016015598
 WO2016015597
 WO2016015605
 WO2016015604
 WO2012066508
 WO2004004632
 WO2011026911
 WO2011026904
 WO2011101409
 WO2006074985
 WO2012061156
 WO2010000913
 WO2010009155
 WO0183469
   WHO DRUG INFORMATION, vol. 27, no. 2, 2013, pages 172
   GALIE ET AL., ERJ, vol. 34, no. 6, December 2009 (2009-12-01), pages 1219 - 63
   SCHERMULY, R.T. ET AL.: "Mechanisms of disease: pulmonary arterial hypertension", NATURE REVIEWS. CARDIOLOGY, vol. 8, 2011, pages 443 - 455, XP037075466, DOI: 10.1038/nrcardio.2011.87

DOI:   http://dx.doi.org/10.1038/nrcardio.2011.87
   HUMBERT, M.GHOFRANI, H.A.: "The molecular targets of approved treatments for pulmonary arterial hypertension", THORAX, vol. 71, 2016, pages 73 - 83
   GUIGNABERT, C ET AL.: "Pathogenesis of pulmonary arterial hypertension: lessons from cancer", EUROPEAN RESPIRATORY REVIEW : AN OFFICIAL JOURNAL OF THE EUROPEAN RESPIRATORY SOCIETY, vol. 22, 2013, pages 543 - 551
   PULLAMSETTI, SS ET AL., AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2016, 14 September 2016 (2016-09-14)
   HEPPE, C.M. ET AL., VASCULAR PHARMACOLOGY, vol. 83, 2016, pages 17 - 25
   NATURE MEDICINE, vol. 20, 2014, pages 1289 - 1300
   CIUCLAN, L. ET AL.: "Imatinib attenuates hypoxia-induced pulmonary arterial hypertension pathology via reduction in 5-hydroxytryptamine through inhibition of tryptophan hydroxylase 1 expression", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 187, 2013, pages 78 - 89
   SCHERMULY, R.T. ET AL.: "Reversal of experimental pulmonary hypertension by PDGF inhibition", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 115, 2005, pages 2811 - 2821, XP008056354, DOI: 10.1172/JCI24838

DOI:   http://dx.doi.org/10.1172/JCI24838
   JOHNSON DGWALKER CL: "Cyclins and Cell Cycle Checkpoints", ANNU. REV. PHARMACOL. TOXICOL., vol. 39, 1999, pages 295 312
   ANNU. REV. CELL. DEV. BIOL., vol. 13, 1997, pages 261 291
   CHARRON, T. ET AL.: "The cell cycle: a critical therapeutic target to prevent vascular proliferative disease", THE CANADIAN JOURNAL OF CARDIOLOGY, vol. 22, 2006, pages 41B - 55B
   STENMARK, K.R. ET AL.: "Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure", AMERICAN JOURNAL OF PHYSIOLOGY. LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, vol. 297, 2009, pages L1013 - 1032
   LANG, M. ET AL.: "The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats", PLOS ONE, vol. 7, 2012, pages e43433
   STRINGER ET AL.: "Catheterization of the pulmonary artery in the closed-chest rat", J. APPL. PHYSIOL., vol. 51, 1981, pages 1047 - 1050
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.